Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-06

Study Completion Date

2023-06-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hyperglycemia is seen in approximately 30% of patients who do not have a history of diabetes and undergo general surgery. Hyperglycemia in this setting is associated with increased risk of postoperative complications. The purpose of this study is to investigate risk factors for developing high sugars during the time of surgery, and if these high sugars can be prevented by the use of an injectable diabetes medication (dulaglutide) prior to surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia?

NCT00468494

General Anesthesia Hyperglycemia

COMPLETED

Diabetes in the Perioperative Period

NCT00738114

Hyperglycemia Diabetes

COMPLETED

SHOrt-term Glycemic Control for Reducing Post-SURGical Complications

NCT06334068

Diabetes Uncontrolled Diabtetes

COMPLETED NA

Outcomes With Tight Control of Hyperglycemia in Cardiac Surgery Patients

NCT00282698

Cardiac Surgical Procedures Hyperglycemia

COMPLETED PHASE3

Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery

NCT00328094

Peripheral Vascular Disease Abdominal Aortic Aneurysm

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Stress hyperglycemia (SH), defined as a blood glucose \>140 mg/dl in hospitalized patients without a prior history of diabetes mellitus (DM) is associated with increased risk of complications and mortality compared to patients with normoglycemia and with known history of DM. Increased counterregulatory hormones (cortisol, glucagon, epinephrine, growth hormone), free fatty acids, inflammation and oxidative stress are likely involved in the pathogenesis of impaired insulin secretion and action leading to stress hyperglycemia. However, no prospective studies have comprehensively examined preoperative glycemic control profiles and their association with the incidence, clinical predictors and underlying mechanisms of SH in general surgical patients. Accordingly, the researchers propose a prospective study investigating clinical, metabolic and inflammatory/oxidative stress biomarker profiles leading to SH. This study will use continuous glucose monitoring (CGM) technology to fully characterize the onset, duration and severity of SH during the perioperative period.

Given the association between stress hyperglycemia and poor hospital outcomes, this study aims to determine if the prevention of stress hyperglycemia is feasible with the single administration of a weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA), a common medication used to treat patients with established diabetes. In addition, the researchers will explore the role of beta-cell function, insulin resistance, and inflammation on the pathogenesis of stress hyperglycemia.

The goals of this study are to: 1) conduct an extensive analysis of preoperative glycemic control and its relationship to clinical, metabolic and biomarker profiles of SH in a high-risk population, and 2) conduct a pilot randomized controlled trial to prospectively determine if single dose use of dulaglutide can improve perioperative glycemic control compared to insulin administration (standard-of-care). Patients qualifying for the study will be approached at their preoperative clinic visit and invited to participate in the prospective observational study arm (Aim 1), and in the interventional trial for prevention of SH with dulaglutide (Aim 2) if they meet inclusion criteria based on oral glucose tolerance testing (OGTT) or lab testing performed for Aim 1. Within 72 hours prior to planned surgery, consented patients will present to the clinical research center (CRC) to undergo evaluation with OGTT and lab testing with CGM placement. Those patients with OGTT or lab results consistent with a diagnosis of prediabetes or newly diagnosed diabetes will be asked if they would like to participate in Aim 2. Patients consenting to participate in Aim 2 will be randomized to receive a subcutaneous injection of dulaglutide 0.75 mg or placebo during the CRC visit, and glycemic control parameters will be followed postoperatively during surgical admission (up to 14 days). In addition to the above, baseline and postoperative levels of serum inflammatory and oxidative stress markers will be obtained to provide further information regarding beta-cell function and insulin resistance in relation to the development of stress hyperglycemia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperglycemia Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dulaglutide

Participants randomized to receive dulaglutide within 72 hours prior to a planned surgery.

Group Type EXPERIMENTAL

Dulaglutide

Intervention Type DRUG

A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.

Continuous glucose monitor (CGM), blinded

Intervention Type DEVICE

Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.

Placebo

Participants randomized to receive a placebo to match dulaglutide within 72 hours prior to a planned surgery.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.

Continuous glucose monitor (CGM), blinded

Intervention Type DEVICE

Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dulaglutide

A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.

Intervention Type DRUG

Placebo

A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.

Intervention Type DRUG

Continuous glucose monitor (CGM), blinded

Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Trulicity FreeStyle Libre Pro

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women without known history of diabetes with ages between 45 and 80 years undergoing non-cardiac general or vascular surgery
* BMI ≥30 kg/m2 and pre-DM or DM by OGTT or HbA1c

Exclusion Criteria

* Patients prescribed or taking antihyperglycemic medications
* Patients undergoing cardiac surgery or patients anticipated to require ICU care
* Patients expected to be admitted less than 48-72 hours after surgery
* Severely impaired renal function (eGFR \< 30 mL/min) or clinically significant hepatic failure
* Treatment with oral (equivalent to prednisone \> 5 mg/day) or injectable corticosteroids
* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study; unable to consent
* Pregnant or breast feeding at time of enrollment
* Prisoners
* Patients undergoing gastrointestinal surgery or at high risk for gastrointestinal obstruction/ileus or expected to require gastrointestinal suction
* Patients with delayed gastric emptying, pancreatic or gallbladder disease
* Patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2)

Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No